Inhibits integrin binding to RGD motifs
CAS：99896-85-2
分子式：C12H22N6O6
分子量：346.34
纯度：98%
存储：Store at -20°C

Background:

Synthetic peptides containing the arginine-glycine-aspartate (RGD) were extensively used as inhibitors of integrin-ligand interactions in studies of cell adhesion, migration, growth and differentiation, since the RGD motif is an integrin-recognition motif found in many ligands.

In vitro: RGD peptide can induce apoptosis in the absence of signals and integrin-mediated cell clustering. Previous study demonstrates that RGD peptides promote apoptosis through activation of conformation changes enhancing pro-caspase-3 activation and autoprocessing [1].

In vivo: Anima study suggested that the RGD-4C-FITC-peptide bound to both endothelial and tumor cells in vivo and that peptide targeting should allow the delivery of therapeutic drugs to both endothelial and tumor cells [2].

Clinical trials: Currenlty no clinical data are available.

参考文献:
[1] Nature.  1999 Feb 11;397(6719):534-9.
RGD peptides induce apoptosis by direct caspase-3 activation. 
Buckley CD1, Pilling D, Henriquez NV, Parsonage G, Threlfall K, Scheel-Toellner D, Simmons DL, Akbar AN, Lord JM, Salmon M. 
[2] Cancer Res.  2002 Sep 15;62(18):5139-43. Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo.  Zitzmann S1, Ehemann V, Schwab M.